Matthew Levy

Matthew is a nucleic acid chemist, biochemist, molecular biologist, and biotechnologist with more than 20 years of experience with leadership roles in academia as a Principal Investigator and head of laboratory work and industry in his roles as Vice President, Chief Scientific Officer, and co-founder. He is an expert in engineering nucleic acids, proteins, and other functional oligonucleotides, particularly in developing aptamers for targeting cell surface receptors. Before joining Creyon, Matthew served as the Head of Discovery at Vitrisa Therapeutics. Prior to that, he held a position as Associate Professor of Biochemistry at the Albert Einstein College of Medicine in New York, where he ran a successful research program for 10 years focused on developing new technologies and approaches using nucleic acid aptamers as well as engineered proteins for both diagnostic and therapeutic purposes. He has authored more than 50 peer-reviewed publications and has 9 issued patents. He received his B.S. in Biochemistry and his M.S. in Chemistry at the University of California San Diego, and went on to obtain his Ph.D. at the University of Texas at Austin. Matthew also currently serves as Scientific Advisor to Drive Therapeutics, a company he co-founded, and Oak Bay Bio, two aptamer companies focused on developing ocular therapeutics.